Bank of Nova Scotia Raises Stock Position in Ralliant Corporation $RAL

Bank of Nova Scotia grew its stake in shares of Ralliant Corporation (NYSE:RAL) by 571.1% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 162,400 shares of the company’s stock after acquiring an additional 138,200 shares during the period. Bank of Nova Scotia’s holdings in Ralliant were worth $6,754,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Sei Investments Co. lifted its holdings in shares of Ralliant by 193.7% in the 1st quarter. Sei Investments Co. now owns 182,342 shares of the company’s stock worth $7,583,000 after buying an additional 120,248 shares during the period. Walleye Capital LLC purchased a new position in shares of Ralliant during the first quarter valued at $4,525,000. First Trust Advisors LP increased its stake in shares of Ralliant by 7.7% during the first quarter. First Trust Advisors LP now owns 95,937 shares of the company’s stock valued at $3,990,000 after buying an additional 6,897 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Ralliant by 60.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,314,834 shares of the company’s stock valued at $54,669,000 after acquiring an additional 496,171 shares in the last quarter. Finally, Scarborough Advisors LLC bought a new stake in shares of Ralliant in the first quarter valued at about $56,000.

Ralliant Trading Up 0.5%

Shares of NYSE RAL opened at $69.75 on Tuesday. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05. The stock has a market capitalization of $7.81 billion and a P/E ratio of -6.38. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $75.41. The business has a fifty day moving average price of $66.65 and a 200 day moving average price of $53.94.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company had revenue of $534.60 million for the quarter. The firm’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities research analysts expect that Ralliant Corporation will post 2.64 EPS for the current fiscal year.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is currently -1.83%.

Analyst Ratings Changes

A number of research firms recently weighed in on RAL. Oppenheimer upped their price objective on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. Zacks Research raised shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 30th. Truist Financial restated a “buy” rating and issued a $68.00 price target (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Barclays upped their price target on shares of Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $73.00.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.